Adam Jourdan and Ben Hirschler
China fined GlaxoSmithKline Plc a record 3 billion yuan ($490 million) on Friday for bribing doctors to use its drugs, underlining the risks of doing business there while also ending a damaging chapter for the British drugmaker.
A court in the southern city of Changsha also sentenced Mark Reilly, the former head of GSK in China, and other GSK executives to between two and four years in jail, according to state news agency Xinhua.